MERGER REVIEW THRESHOLDS FOR BIOTECH ACQUISITIONS

1. INTRODUCTION

Merger review thresholds for biotechnology acquisitions determine when the acquisition of a biotechnology company, pharmaceutical enterprise, genetic research organization, diagnostic laboratory, or biological technology platform must be notified to competition authorities for regulatory examination.

Biotechnology acquisitions frequently involve valuable intellectual property, patents, genomic databases, research pipelines, biologics manufacturing facilities, clinical trial assets, and exclusive licensing arrangements. Such transactions can create competition concerns even when the target company has relatively limited revenue because its scientific technology or research potential may be commercially significant.

In India, merger review is principally governed by the Competition Act, 2002, administered by the Competition Commission of India (CCI). The framework seeks to prevent combinations that cause or are likely to cause an appreciable adverse effect on competition (AAEC) in the relevant Indian market.

2. LEGAL FRAMEWORK GOVERNING BIOTECH ACQUISITIONS

The principal provisions are:

A. Section 5 – Definition of Combinations

Section 5 identifies acquisitions, mergers, and amalgamations that qualify as combinations under the Competition Act. Its thresholds include specified asset and turnover limits, together with the deal value threshold introduced through the Competition (Amendment) Act, 2023.

B. Section 6 – Regulation of Combinations

Section 6 prohibits combinations that cause or are likely to cause an appreciable adverse effect on competition in India. Qualifying transactions must obtain the required approval before consummation, subject to applicable exemptions.

C. Section 20 – Inquiry into Combinations

The CCI can examine combinations and investigate their competitive implications within the statutory framework.

D. Section 29 – Procedure for Investigation

This provision establishes the procedure for examining combinations that raise competition concerns, including issuing notices and seeking explanations from the parties.

E. Competition (Combinations) Regulations, 2024

These regulations provide procedural requirements for notifying combinations, filing information, and examining transactions under the amended competition framework.

3. FINANCIAL MERGER REVIEW THRESHOLDS

Traditional merger review thresholds consider the assets and turnover of the acquiring enterprise, the target enterprise, or the combined entities, as applicable.

The Competition Act prescribes domestic and worldwide thresholds, with different tests for individual parties and groups.

The relevant statutory thresholds include:

Combined Indian assets exceeding ₹2,000 crore or combined Indian turnover exceeding ₹6,000 crore.

Combined worldwide assets exceeding USD 1 billion, including at least ₹1,000 crore in India, or worldwide turnover exceeding USD 3 billion, including at least ₹3,000 crore in India.

Acquirer-level thresholds of Indian assets exceeding ₹1,000 crore or Indian turnover exceeding ₹3,000 crore.

Worldwide acquirer-level assets exceeding USD 500 million, including at least ₹500 crore in India, or worldwide turnover exceeding USD 1.5 billion, including at least ₹1,500 crore in India.

The corresponding group-level thresholds are also relevant under Section 5.

These figures must be read with the statutory definitions, applicable rules, and exemptions rather than treated as automatic notification requirements in isolation.

4. DEAL VALUE THRESHOLD FOR BIOTECH ACQUISITIONS

The Competition (Amendment) Act, 2023 introduced a significant change through Section 5(d).

A transaction involving an acquisition, merger, or amalgamation may qualify as a combination where its value exceeds ₹2,000 crore and the target enterprise has substantial business operations in India.

This provision is particularly important for biotechnology acquisitions because a startup may possess valuable gene-editing technology, drug-development candidates, proprietary biological datasets, or patented diagnostic systems despite having limited current revenue.

The deal value threshold therefore captures certain transactions that might escape traditional asset and turnover tests.

5. REVISED FINANCIAL THRESHOLDS APPLICABLE FROM 2024

The Ministry of Corporate Affairs revised the financial thresholds through Notification S.O. 1130(E), dated 7 March 2024.

Worldwide thresholds with Indian components are also applicable:

Enterprise level: USD 1.25 billion assets, including at least ₹1,250 crore in India, or USD 3.75 billion turnover, including at least ₹3,750 crore in India.

Group level: USD 5 billion assets, including at least ₹1,250 crore in India, or USD 15 billion turnover, including at least ₹3,750 crore in India.

Important correction: These revised figures replace the earlier figures stated in Section 3. The applicable statutory tests operate alternatively: satisfying any one relevant threshold can trigger combination status.

Press Information Bureau+2

6. SMALL TARGET EXEMPTION

The de minimis exemption protects certain acquisitions involving small target enterprises from notification under the ordinary asset and turnover thresholds.

The exemption is particularly relevant to biotechnology startups, research laboratories, and early-stage drug-development companies.

However, parties must examine the applicable government notification and its conditions. The exemption should not automatically be assumed to cover transactions meeting the separate deal value threshold.

7. SUBSTANTIAL BUSINESS OPERATIONS IN INDIA

Under the Competition Commission of India (Combinations) Regulations, 2024, the target must satisfy the prescribed substantial business operations in India (SBOI) criteria for the deal value threshold to apply.

Relevant criteria include:

Indian turnover representing at least 10% of global turnover and exceeding ₹500 crore.

Indian gross merchandise value representing at least 10% of global gross merchandise value and exceeding ₹500 crore.

For digital services, Indian business or end users representing at least 10% of the corresponding global user base.

The ₹500 crore minimum does not apply to the digital-services user criterion. These tests are particularly relevant to biotechnology platforms operating through digital diagnostic services, genomic databases, and technology-enabled healthcare services.

Competition Commission of India+1

8. BIOTECHNOLOGY-SPECIFIC COMPETITION CONSIDERATIONS

Although India does not prescribe separate merger notification thresholds exclusively for biotechnology, the sector presents distinctive competition concerns.

The CCI may examine:

Consolidation of pharmaceutical patents and proprietary technologies.

Acquisition of competing gene-editing platforms.

Control over essential biological research materials.

Exclusive licensing of biotechnology inventions.

Elimination of emerging competitors.

Access restrictions concerning clinical research infrastructure.

Vertical integration between biotechnology manufacturers and distributors.

Potential foreclosure of competing diagnostic and therapeutic developers.

The acquisition of patents, exclusive licences, or relevant business divisions may also require assessment as acquisitions of assets or control under the Act.

9. IMPORTANT JUDICIAL DECISIONS AND CASE LAWS

1. Competition Commission of India v. Thomas Cook (India) Ltd. (2018) 6 SCC 549

Authority: Direct authority.

The Supreme Court considered the consequences of failing to notify a notifiable combination. It upheld the CCI's power to impose a penalty for failure to comply with the advance-notification requirement. The decision establishes that transaction structuring cannot be used to defeat merger notification obligations.

2. SCM Solifert Ltd. v. Competition Commission of India (2018) 6 SCC 631

Authority: Direct authority.

The Supreme Court examined acquisitions of shares in Mangalore Chemicals and Fertilisers Limited. It emphasized that mandatory notification must precede consummation where the statutory requirements are satisfied. Subsequent approval does not automatically cure an earlier notification violation. This is particularly important when biotech acquisitions are completed through successive share purchases.

3. Sun Pharmaceutical Industries Ltd. and Ranbaxy Laboratories Ltd., Combination Registration No. C-2014/05/170 (2014)

Authority: Direct competition-law precedent.

The CCI examined the proposed pharmaceutical merger and identified competition concerns in seven formulation markets. It required divestment of specified products before allowing the merger to take effect. The decision demonstrates how pharmaceutical consolidation, overlapping products, and market concentration influence merger review.

4. Bayer AG / Monsanto Company, CCI Combination Order (2018)

Authority: Direct competition-law precedent.

The CCI examined Bayer's acquisition of Monsanto, involving biotechnology traits, seeds, herbicides, and agricultural technologies. Approval was granted subject to divestitures and licensing commitments, including fair, reasonable, and non-discriminatory licensing conditions. The decision is particularly relevant to biotechnology acquisitions involving patents, genetic traits, and agricultural innovation.

5. Independent Media Trust v. CCI, Combination Registration No. C-2012/03/47 (2012)

Authority: Direct competition-law precedent.

The CCI examined financial and contractual arrangements that provided an acquirer with decisive influence over another enterprise. The decision demonstrates that control may arise through contractual rights and convertible financial instruments, even without an immediate transfer of majority ownership. This principle is relevant to biotechnology investment agreements containing strategic veto rights and governance arrangements.

6. Ultratech Cement Ltd., Combination Registration No. C-2015/02/246 (2018)

Authority: Analogous competition-law precedent.

The CCI examined the concept of material influence and the circumstances in which shareholder rights may constitute control. The decision explains why board representation, strategic decision-making rights, and contractual arrangements must be considered when assessing whether an acquisition requires notification.

7. Baxalta Incorporated / Baxter International Inc., Combination Registration No. C-2015/07/297

Authority: Direct competition-law precedent.

This cross-border transaction illustrates the importance of assessing the global transaction structure and its Indian component. The CCI's guidance concerning global agreements emphasizes that parties cannot necessarily postpone Indian merger notification until a separate local transaction document is executed.

These decisions establish important principles concerning notification, control, transaction structure, and competitive effects.

IndiaCode+6

10. PENALTIES AND REGULATORY CONSEQUENCES

Failure to notify a qualifying combination can result in penalties under Section 43A of the Competition Act, 2002.

Other consequences may include:

Investigation into failure to notify.

Monetary penalties for gun-jumping.

Directions to modify the proposed transaction.

Divestiture of overlapping businesses or intellectual property.

Restrictions on exclusive licensing arrangements.

Prohibition of combinations likely to cause an appreciable adverse effect on competition.

Parties should therefore obtain competition-law clearance before implementing a notifiable acquisition.

11. PRACTICAL COMPLIANCE REQUIREMENTS

Biotechnology companies planning acquisitions should:

Calculate the combined assets and turnover of relevant parties and groups.

Determine the total transaction value, including direct, indirect, immediate, deferred, and other valuable consideration.

Identify patents, licences, research assets, and intellectual property being transferred.

Examine whether the target satisfies the SBOI criteria.

Assess applicable exemptions and filing requirements.

Identify overlapping pharmaceutical products and research pipelines.

Prepare the required CCI notification.

Avoid premature integration or transfer of control before approval.

12. CONCLUSION

Merger review thresholds for biotechnology acquisitions in India are governed principally by Sections 5, 6, 20, and 29 of the Competition Act, 2002, together with the Competition Commission of India (Combinations) Regulations, 2024.

The introduction of the ₹2,000 crore deal value threshold has expanded merger scrutiny beyond traditional financial thresholds. This is particularly significant for biotechnology startups possessing valuable patents, genetic technologies, biological research platforms, and innovative drug-development pipelines.

The decisions in Thomas Cook, SCM Solifert, Sun Pharma–Ranbaxy, and Bayer–Monsanto demonstrate the importance of advance notification, appropriate assessment of control, protection of innovation, and prevention of anti-competitive consolidation.

Ultimately, effective merger review must balance commercial investment and technological development with market competition, research innovation, consumer welfare, and access to essential biotechnology products.